Dr. Woyach Discusses the Efficacy Findings from the RESONATE Trial
Jennifer Woyach, MD, assistant professor of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the efficacy findings from the phase III RESONATE trial, which compared ibrutinib versus ofatumumab in relapsed or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma.
Woyach says the study showed that the efficacy of ibrutinib was superior to ofatumumab when given as a single agent. The study also showed response rates were significantly better with ibrutinib [ORR=42.6 vs 4.1% (P <0.0001), ORR+PR with lymphocytosis=62.6 vs 4.1%].
While progression-free survival was not yet reached in the ibrutinib arm, Woyach says the progression-free survival was only about 8 months in the ofatumumab arm.